Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Yajun Xu United States

Early stage Biotech investment (VC)
Website:
https://www.hongseninvestment.com/
Partnering Objectives
Headquartner in China
Yes
Hongsen Investment
Managing partner 

Dr. June Xu China

医疗基金
Website:
Redhillcapital.cn
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Investment opportunities
Headquartner in China
Yes
丹麓资本
Senior Associate 

Ms. Rosa Xu China

· About Us
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.

· Investment Cases

Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..

· Investment Preference

We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.

Website：www.hongxingerke.com
Website:
www.hongxingerke.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
No clear limits
Headquartner in China
Yes
Hongxing Erke Investment Company
Investment Manager 
Functionality
Investment

Mr. Adam Xu China

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.
Website:
www.trustwe.com
Company Size (Fulltime employees)
11-50
Year of foundation
2007
Partnering Objectives
Please specify your partnering goal
Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals.
Headquartner in China
Yes
Shanghai T&W Pharmaceutical Co., Ltd.
BD Director 
Functionality
Business Development

Wenfeng Xu United States

Innovative biologics for cancer and other patients' unmet needs
Website:
Hengenix.com
Company Size (Fulltime employees)
1001-5000
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
co-dev
Headquartner in China
Yes
Biotech/Pharma Category
Hengenix
VP Research 
Functionality
Research and Development

wenlian xu China

New drug development
Website:
GHtherapeutics.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
GH Therapeutics
CEO 

Mr. Kenneth Xu China

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Website:
www.genova.cn
Company Size (Fulltime employees)
201-500
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
To work with a reputable pharmaceutical, or medical institute, or government agency, on scientific and business development of Novaferon as an antiviral drug for COVID-19. Cooperating specifically on organizing and managing international clinical trials, laboratory and animal studies for COVID-19. Licensing rights for COVID-19 applications of Novaferon in defined territories, further equity cooperation might be accordingly considered
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Genova Inc
Vice President & Corporate Secretary 
Functionality
Business Development

Mr. Paul Xu United States

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.
Website:
www.shenzhenoffice.org
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
providing consulting service for entities interested to find opportunities in Shenzhen
Headquartner in China
Yes
North American Rep. Office of Shenzhen
Business Development Specialist 
Functionality
Business Development

John Xu United States

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800

Website:
www.Abpro.com
Partnering Objectives
Headquartner in China
No
Abpro
SVP 

Mrs. Shirley Xu China

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Website:
http://www.yonghuacapital.com.cn/
Partnering Objectives
Headquartner in China
Yes
Yonghua Capital
Executive Director 
Functionality
Investment